GlassScriptPhysician profile
Brooke R Glessing
NPI 1447499819
$21,170.04
in general payments reported to CMS, 2019-2025
20 companies · $3,981 in 2025
The $3,981 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $21.96 · 2022: $500 · 2023: $2,505 · 2024: $14K · 2025: $3,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $3,773 · Food and Beverage: $3,239 · Consulting Fee: $2,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,625.00 |
| Travel and Lodging | $3,773.08 |
| Food and Beverage | $3,239.15 |
| Consulting Fee | $2,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15,254.79 | 2019-2025 | Axios, General - Endochoice, Exalt Model D |
| US Endoscopy | $3,250.00 | 2022-2025 | |
| Apollo Endosurgery US INC | $1,199.78 | 2023 | Overstitch Endoscopic Suturing System |
| Erbe USA INC | $290.00 | 2024-2025 | Vio3 |
| Abbvie INC. | $148.80 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $145.49 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $137.94 | 2024 | |
| Cook Medical LLC | $134.04 | 2025 | Echotip Insight |
| Allergan, INC. | $125.00 | 2019 | |
| Vivus LLC | $103.58 | 2019-2020 | |
| Steris Corporation | $89.92 | 2025 | |
| Pfizer INC. | $83.59 | 2024-2025 | |
| Madrigal Pharmaceuticals | $64.05 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $28.52 | 2025 | Entyvio |
| Organon LLC | $24.96 | 2025 | Renflexis, Hadlima |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20.93 | 2025 | Tremfya |
| Ucb, INC. | $18.30 | 2019 | |
| Sandoz INC. | $17.40 | 2025 | Hyrimoz |
| Mauna Kea Technologies, INC. | $16.89 | 2024 | |
| Amgen INC. | $16.06 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Glessing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.